-5.3%
PG vs MRNA
+511.3%
-516.6%
-15.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.3% | -2.2% | +1.9% | -0.3% |
| 7D | +1.9% | +5.5% | -3.6% | +1.8% |
| 30D | -0.2% | +158.7% | -159.0% | -1.1% |
| 3M | +4.8% | +182.1% | -177.3% | +4.0% |
| 6M | -6.1% | +151.8% | -157.9% | -6.8% |
| YTD | +4.5% | +393.6% | -389.1% | +3.5% |
| 1Y | -5.3% | +499.5% | -504.8% | -7.3% |
| All | -5.3% | +511.3% | -516.6% | -7.3% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling